<DOC>
	<DOCNO>NCT02861872</DOCNO>
	<brief_summary>Ovarian cancer third common gynecological malignancy worldwide . Because late , aspecific symptom , disease usually diagnose advanced stage . Most patient experience recurrence die result disease within 5 year . Treatment combination surgical debulking systemic administer chemotherapy . Intra-peritoneal ( IP ) chemotherapy currently consider effective treatment . In patient least optimal surgical debulking , lead improvement life expectancy 50 66 month . IP administration chemotherapeutic agent still common practice . Furthermore recent study reveal cancer cell express variety tumor antigen , target immune system . Also ovarian cancer show evidence role immune system clinical outcome . Novel insight mechanism action chemotherapy indicate efficacy chemotherapeutic intervention dependent modulation immune system . The impression exist since IP chemotherapy use , relatively recurrence outside abdominal cavity observe . As yet , study describe pharmacokinetics pharmacodynamics IP administer cisplatin paclitaxel blood circulation . The investigator propose study use aspiration fluid IP cavity biomarker efficacy chemotherapy intervention , monitor effect chemotherapy IP tumor cell peritoneal cavity monitor effect chemotherapy immune cell present IP cavity . As well investigator propose correlate presence amount tumor cell peritoneal fluid debulking efficacy CA 125 level . Secondary investigator intend determine pharmacokinetics cisplatin paclitaxel administer IP cavity central circulation ( plasma ) well peritoneal fluid . In observational explorative study woman , age young 70 year , receive standard IP chemotherapy advance epithelial ovarian cancer , adequate physical biochemical state receive chemotherapy include . Immunological cell count , tumor marker , immunological cell pathway activation plasma concentration cisplatinum paclitaxel venous blood fluid aspirate abdominal cavity measure .</brief_summary>
	<brief_title>Intra-peritoneal Chemotherapy Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Patients receive IP chemotherapy therefore meeting follow criterion : Primary epithelial ovarian carcinoma FIGO stage III ; Optimal complete primary debulking ( tumor rest ≤ 1cm ; WHO 0 2 ; Adequate hematological function : WBC ≥ 3 . 106/L en Platelets ≥ 100 . 106/L , Adequate renal function ( Creatinine clearance &gt; 60 ml/min ( Cockcroft ) ) Adequate liver function test ( bilirubin and/or transaminase &lt; 1.25 UNL ) A potential subject meet follow criterion exclude participation study ( accord standard IP chemotherapy ) : Intestinal stoma proximal flexura lienalis ; Postoperative sepsis primary debulking ; Haemoglobin &lt; 6.0 mMol/L Extended intraperitoneal adhesion ; Neurotoxicity grade &gt; 1 ; Previous chemotherapy ovarian carcinoma ; Symptomatic hearing loss ; Age &gt; 70 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Intraperitoneal chemotherapy</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>